AstraZeneca PLC's 6-K Report: Euan Ashley Joins DexCom Board!

Here are the key insights extracted from the provided section of the financial report:

1. Company Overview:

• Name: AstraZeneca PLC
• Headquarters: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
• Business Focus: AstraZeneca is a global biopharmaceutical company engaged in the discovery, development, and commercialization of prescription medicines primarily in Oncology, Rare Diseases, and BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology).

2. Filing Type:

• Form 6-K: The report is submitted under Form 6-K, a form used by foreign companies to report information to the SEC.

3. Date of Report:

• The report is dated October 28, 2025.

4. Director Appointment:

• Euan Ashley has been appointed as a director of DexCom, Inc., effective October 24, 2025. This information is important for stakeholders as it relates to changes in the company's governance structure.

5. Compliance Information:

• The announcement regarding the director's appointment is made in compliance with Listing Rule 6.4.9 (2).

6. Regulatory Filing Information:

• The company indicates it files annual reports under Form 20-F.
• The registrant has not furnished the information to the Commission pursuant to Rule 12g3-2(b).

7. Contacts for Further Information:

• Contact information for Investor Relations and Media is provided, indicating a structured approach to investor communications.

8. Signature:

• The report is signed by Matthew Bowden, the Company Secretary, affirming its authenticity.

This report serves to inform investors and stakeholders about significant changes in executive appointments and maintains compliance with regulatory requirements, reflecting AstraZeneca's commitment to transparency in its governance practices.